Investors

Corporate News & Publications

CLINUVEL's company releases, including archives.

Friday, 16 October 2009 10:00

Annual Report to shareholders

Annual Report to shareholders
Friday, 23 October 2009 10:00

Appendix 3B

Appendix 3B
Wednesday, 28 October 2009 11:00

Appendix 4C

Appendix 4C
Wednesday, 04 November 2009 11:00

Expiry of Unlisted Share Options

Expiry of Unlisted Share Options
Tuesday, 10 November 2009 11:00

Open Briefing. Clinuvel. CEO on MAA application to EMEA

Open Briefing. Clinuvel. CEO on MAA application to EMEA
Wednesday, 18 November 2009 11:00

Clinuvel AGM 2009 Chair and CEO Presentation

Clinuvel AGM 2009 Chair and CEO Presentation
Wednesday, 18 November 2009 11:00

Results of Meeting

Results of Meeting
Thursday, 26 November 2009 11:00

Appendix 3Y

Appendix 3Y
Monday, 30 November 2009 11:00

The European Medicines Agency grants Clinuvel SME status

The European Medicines Agency grants Clinuvel SME status
Pilot study evaluating afamelanotide as adjunct therapy in systemic photodynamic therapy (PDT) Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it had obtained positive results from an experimental randomised placebo-controlled Phase II trial (CUV025) evaluating the photoprotective effect of afamelanotide in 16 patients. Objectives and results The objective of this exploratory trial was to determine the effect of a single 16mg dose of afamelanotide on the quality of life and phototoxicity in patients undergoing PDT. The trial was conducted by 4 French academic departments of gastro-enterology. Patients were followed up during 90 days. In total 16…

Quick Links